Alzheimer's disease; taking the edge off with cannabinoids?
about
Cannabinoids for the treatment of dementiaCannabinoids for the treatment of dementiaProlonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice.Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids.Epigenetic regulation of fatty acid amide hydrolase in Alzheimer diseaseEndocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons.Δ9-THC-caused synaptic and memory impairments are mediated through COX-2 signalingDifferential effects of self-reported lifetime marijuana use on interleukin-1 alpha and tumor necrosis factor in African American adults.Nabilone for the Treatment of Dementia-Associated Sexual Disinhibition.Cannabinoids and Dementia: A Review of Clinical and Preclinical Data.The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-β and in the cortex of aged ratsCorrelations between the Memory-Related Behavior and the Level of Oxidative Stress Biomarkers in the Mice Brain, Provoked by an Acute Administration of CB Receptor LigandsInflammation and aging: can endocannabinoids help?Curcumin Attenuates Beta-Amyloid-Induced Neuroinflammation via Activation of Peroxisome Proliferator-Activated Receptor-Gamma Function in a Rat Model of Alzheimer's Disease.The endocannabinoid system as a target for the treatment of motor dysfunction.Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease.Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.Mitochondrial Ferritin Deletion Exacerbates β-Amyloid-Induced Neurotoxicity in MiceThe multiplicity of action of cannabinoids: implications for treating neurodegeneration.Current perspectives on pharmacotherapy of Alzheimer's disease.Neurobiological aspects of Alzheimer's disease.Medicinal plants and dementia therapy: herbal hopes for brain aging?The therapeutic potential of the endocannabinoid system for Alzheimer's disease.Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier.From Chemotherapy-Induced Emesis to Neuroprotection: Therapeutic Opportunities for 5-HT3 Receptor Antagonists.New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.Cannabinoids and their actionsIdentification of potential herbal inhibitor of acetylcholinesterase associated Alzheimer's disorders using molecular docking and molecular dynamics simulation.Protective effect of centipedegrass against Aβ oligomerization and Aβ-mediated cell death in PC12 cells.A role for p53 in the regulation of lysosomal permeability by delta 9-tetrahydrocannabinol in rat cortical neurones: implications for neurodegeneration.Tropisetron attenuates amyloid-beta-induced inflammatory and apoptotic responses in rats.Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model.Solid lipid curcumin particles provide greater anti-amyloid, anti-inflammatory and neuroprotective effects than curcumin in the 5xFAD mouse model of Alzheimer's disease.Effect of mesenchymal stem cells and galantamine nanoparticles in rat model of Alzheimer's disease.
P2860
Q24241582-17C0FCE6-B825-4840-9C02-A244B02880F5Q24242873-5B9E2A07-9694-45BC-966D-12699527CF59Q30506148-2FC23086-8C52-407C-96D3-CD8F94B72F45Q33914305-C2193FA1-0ADA-48F1-957A-8CB8C79CF7B3Q34312272-4C98557D-8494-4CCB-9BFF-14BC4136D311Q34352311-DFB7B8E3-3B03-4C45-938E-ED85161D9320Q34387254-4F737F45-A8CA-4486-AAB8-1A9CEBF0E99AQ35587290-EE6085D2-E8FE-4614-83B8-BA968A068399Q35746640-58FB3501-D548-40A5-9D27-EE28CB809B5FQ36155898-5C5A5462-FCDC-4819-BEAB-EB84082555BFQ36298496-8F8D96AA-2DDF-4774-9901-88AFEC7FC315Q36453850-71B30CA9-E7BA-446C-ACD3-391DDBFE36FDQ37133525-A5B735A9-5AD6-4DC3-BC10-B2321B10E887Q37188527-68F1E74D-6593-4442-900E-63947002EF30Q37394164-C812ABEE-F2A8-4FF3-891D-0533003DEB9CQ37553341-32761FD5-D93B-4C8D-801E-F23D79922686Q37559812-542CF28D-740F-43C1-9D22-108A50269A33Q37612064-E107457F-1D37-4575-97D5-31902362EF70Q37793366-EABCF6E5-EB14-4BAD-932F-59EB2BA53B77Q37827489-B2048B43-D9DF-44CC-B601-E13E58CB1501Q37840095-53312881-5C5B-4333-8F55-F43845C4E1C0Q37954368-9C5F7A4A-D725-4D32-9624-EA30C13B20B7Q37997020-B5115D4A-879A-48D1-BC09-F095D106C4B9Q38220272-27CD6A87-A49C-43A5-A3D1-C9C1BBBC17AFQ38265931-C3BAA203-D2C3-48E9-8FCC-0FCBD3AABD35Q38395251-0C3E9C9A-D892-44C2-913A-DF7C8E20A842Q39580210-E1E4E0ED-DDFA-4AE5-8B23-34D5B2CBE4A7Q41783735-2BA0ECE1-188D-47FC-A9A3-84F83B05F24DQ46746734-4BC0B605-B1DA-4611-BA54-38C61AA9F307Q46772992-13FA0F5F-D13C-4ECC-9873-46059E4C5009Q47797919-EE5A449F-D5DA-457B-8386-FD8091192550Q50230005-0014E12E-956B-49F1-8D26-79B4716A6E31Q50321909-7B9901FB-4E13-4BC1-9D03-75BFCB044B11Q50627263-6026DA67-BAEB-41F3-A23D-6EFC5A20DC03
P2860
Alzheimer's disease; taking the edge off with cannabinoids?
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Alzheimer's disease; taking the edge off with cannabinoids?
@ast
Alzheimer's disease; taking the edge off with cannabinoids?
@en
Alzheimer's disease; taking the edge off with cannabinoids?
@nl
type
label
Alzheimer's disease; taking the edge off with cannabinoids?
@ast
Alzheimer's disease; taking the edge off with cannabinoids?
@en
Alzheimer's disease; taking the edge off with cannabinoids?
@nl
prefLabel
Alzheimer's disease; taking the edge off with cannabinoids?
@ast
Alzheimer's disease; taking the edge off with cannabinoids?
@en
Alzheimer's disease; taking the edge off with cannabinoids?
@nl
P2860
P3181
P356
P1476
Alzheimer's disease; taking the edge off with cannabinoids?
@en
P2093
V A Campbell
P2860
P304
P3181
P356
10.1038/SJ.BJP.0707446
P407
P577
2007-11-01T00:00:00Z